A large number of innovative drugs actively cut the price, dedicated to 2022 medical insurance negotiations

Author:Kenji Bureau Time:2022.08.09

In 2022, medical insurance negotiations have been negotiated for several months, and various pharmaceutical companies have begun to reduce prices.

On August 8th, Heilongjiang Provincial Pharmaceutical Pharmaceutical Procurement Network issued a notice that in July 2022, the enterprise's independent application price adjustment information was announced, and the publicity period: August 8th to August 10th, 2022.

The Jianzhi Bureau sorted out and found that there were 214 varieties of this price reduction, including: Remine Pharmaceutical Rypinib, Pfizer's Berosley Capsules, Abervis Vennachra, and Bollinger Yinghan. Linko monoclonal anti -resistance and other heavy varieties.

According to the deployment of the State Medical Insurance Bureau, the medical insurance negotiations in 2022 are divided into five stages, from July to August as the application stage, August entered expert review, and September to October is the most intense and fierce medical insurance type negotiation stage.

A number of innovative drugs reduced prices, which undoubtedly prepared for the medical insurance directory in advance. Liang Yi, the chief business officer and president of Greater China, once revealed to the Jianzhi Bureau, "We hope that Ruixi can enter the negotiation catalog."

In addition to innovative drugs, in the quotation of Heilongjiang, a variety of medical insurance drugs such as Liuwei Dihuang Pill (thin film) also increased significantly this time, with a maximum decrease of more than 90%.

The industry generally believes that with the continuous advancement of policies such as drug collection and consistency evaluation, the price space for ordinary "players" will be increasingly smaller and small in the future. return.

Both foreign companies have reduced prices, and in order to complete the sales task

From the perspective of the drug price adjustment list in Heilongjiang Province, the highest unit price product is Berlingeghan's injecting Belinso monoclonal resistance.

Belinso monoclonal anti -anti -resistance (product name: Beliv) is the world's first cell connection molecular drug with CD19 and CD3. In December 2021, China was approved to be listed. It is a special effect of acute lymphocyte leukemia.

Although Bolinger's products are special effects, the leukemia market has not only targeted drugs, but also chemotherapy drugs, as well as some auxiliary treatment. If the Belinso's monoclonal anti -anti -anti -anti -resistance is used to occupy the hospital market quickly, entering medical insurance is an effective means.

In the price adjustment of Heilongjiang, the Belinso monoclonal resistance for 35 μg × 1 bottle per box was reduced from 129,000 yuan to 9,615 yuan, and the price reduction exceeded 25%. Analysts pointed out that if the price reduction or the prelude to medical insurance negotiations, if you want to really enter the catalog, the company may choose to reduce the price when negotiating.

Not only is it a multinational pharmaceutical company, but a large number of domestic pharmaceutical companies have also enthusiastically cut prices.

As a special medicine for the treatment of heart failure, Zuoxi Mengdan injection has been widely used in clinical practice. According to the data of Zha Rongyun, Qilu Pharmaceutical has occupied 80 % of the market, and the rest of the market is controlled by Chengdu Santo Bio.

Obviously, entering the medical insurance directory is an inevitable means to ensure the stable growth of the market in the hospital. The price of 5ml: 12.5mg Zuo Ximen Dan injection from 2300 yuan per branch to 1733.7 yuan. Although the price reduction is only 25%, because there is only one competitor in the market, the industry generally believes that Qilu's possibility of entering medical insurance this time will be relatively high.

In addition, Pfizer's Port Capita Capsules, Changchun Golden Golden Ridotyle Reorganizes Human Growth Hormone Injection, and the Dopsen injection of the Merba Kangjiale, although its own reasons, have different choices to reduce prices.

Analysts pointed out that corporate product medical insurance negotiations are not approved, and it is difficult to complete sales tasks in the public hospital market in the future, and entering the catalog is the only bargaining chip of their competitors.

Medical insurance occupies the mainstream market and pursues thin profits and sales

Price reduction of Chinese medicines is rare before.

Jianzhi Bureau sorted out and found that the price of Liuwei Dihuang Pill (thin film clothing) of each bag of 6.3 grams × 10 bags was 81.66 yuan, and this time Hulunbuir Pine Deer Pharmaceutical Co., Ltd. adjusted the product price to 8.166 yuan per box, the price reduction rate More than 90%.

The price reduction of Songlu Pharmaceutical's Chinese medicine is also amazing. According to the price adjustment list of Heilongjiang, the original hanging network price of 3G/bottle × 10 bottles (cultivated beef and yellow) per box is 995 yuan, and the price after the price adjustment is 99.5 yuan.

Xihuang Wan (cultivated Niuhuang) and Liuwei Dihuang Pills (thin film clothing pills) are all medical insurance medicine, but analysts point out that because Heilongjiang Province has entered a number of provincial -level band procurement alliances, affected by this, the price reduction of related products is also in the institute. Inevitable.

In fact, although the volume procurement has lowered the sales of related varieties, it accounts for 70%of the hospital's market share, not only obtains the dividends of medical insurance reimbursement, but also occupy most of the hospital's market share and squeeze more competitors.

In 2021, China's pharmaceutical industry realized operating income of 3370.75 billion yuan, while the total expenditure of medical insurance funds was 2404.31 billion yuan, which means that medical insurance funds account for 70%of the total industrial revenue. The industry generally believes that medical insurance negotiations are the foundation of the survival and development of pharmaceutical companies. Many varieties are quickly capsule after incorporating the directory, bringing elasticity to the corresponding varieties.

The amount of price exchange is the starting point for the active price reduction of pharmaceutical companies. After all medicines are included in the medical insurance or collection, although the price is cut off a lot, under the amount of collection, the corporate income is guaranteed, the profit is large, and the overall profit level can still be maintained.

Medical insurance collection is continuous behavior, and enterprises can obtain continuous and stable income and profit growth. However, the industry generally believes that the total payment of medical insurance funds is high, so games, balance and overall situation are crucial.